C4X Discovery Holdings PLC Annual Report and Notice of AGM (6660V)
15 December 2021 - 6:00PM
UK Regulatory
TIDMC4XD
RNS Number : 6660V
C4X Discovery Holdings PLC
15 December 2021
C4X Discovery Holdings plc
("C4XD", "C4X Discovery" or the "Company")
Posting of 2021 Annual Report and Notice of AGM
15 December 2021 - C4X Discovery Holdings plc (AIM: C4XD), a
pioneering Drug Discovery company, announces that it has today
published and posted to shareholders the Annual Report and Accounts
for the year ended 31 July 2021 and Notice of the Annual General
Meeting ("AGM") which will be held at Panmure Gordon, One New
Change, London, EC4M 9AF, on 18 January 2022 at 2.00 p.m.
(GMT).
The Annual Report and Accounts and notice of AGM are also
available to view on, and download from, the Company's website at
www.c4xdiscovery.com
- Ends -
Contacts
C4X Discovery Holdings
Mo Noonan, Communications +44 (0)787 6444977
Panmure Gordon (UK) Limited (NOMAD and
Broker)
Freddy Crossley, Emma Earl (Corporate
Finance) +44 (0)20 7886 2500
Rupert Dearden (Corporate Broking)
C4X Discovery Media - Consilium Strategic
Communications
Mary-Jane Elliott, Chris Gardner, Matthew
Neal +44 (0)203 709 5700
Notes to Editors:
About C4X Discovery
C4X Discovery ("C4XD") is a pioneering Drug Discovery company
combining scientific expertise with cutting-edge Drug Discovery
technologies to efficiently deliver world leading medicines, which
are developed by our partners for the benefit of patients. We have
a highly valuable and differentiated approach to Drug Discovery
through our enhanced DNA-based target identification and candidate
molecule design capabilities, generating small molecule drug
candidates across multiple disease areas including inflammation,
oncology, neurodegeneration and addictive disorders. Our
commercially attractive portfolio ranges from early stage novel
target opportunities to late stage Drug Discovery programmes ready
for out-licensing to partners and we have two commercially
partnered programmes with one candidate in clinical
development.
We collaborate with leading pharmaceutical and life sciences
companies to enrich our expertise and take our assets through
pre-clinical and clinical development. Through early-stage
revenue-generating licensing deals, we realise returns from our
high value pre-clinical assets which are reinvested to maximise the
value of our Drug Discovery portfolio.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFFFFFFSLSLIL
(END) Dow Jones Newswires
December 15, 2021 02:00 ET (07:00 GMT)
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From Apr 2024 to May 2024
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From May 2023 to May 2024